Cerebrolysin 60mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Cerebrolysin is a porcine (pig) brain-derived mixture of low-molecular-weight neuropeptides and free amino acids, hypothesized to mimic neurotrophic factors such as BDNF, NGF and GDNF[1][5]. It is marketed in 50+ countries for stroke, dementia and TBI, but is not FDA-approved in the United States and the human evidence is mixed and inconclusive. This page reproduces a research-powder reconstitution scheme for educational reference only. Note: commercial Cerebrolysin is actually a ready-to-use liquid given by clinicians intramuscularly or intravenously — never subcutaneously — so the powder/SC protocol below is not standard medical practice.

Add 3.0 mL bacteriostatic water to one 60 mg vial → 20 mg/mL. Research-powder scheme only; real Cerebrolysin is a ready-to-use liquid.
20 mg/day in Week 1, titrated up to 32 mg/day by Week 4+, with later doses split into AM and PM injections.
At 20 mg/mL, 1 unit = 0.2 mg on a U-100 syringe; so 20 mg = 100 units and 32 mg = 160 units (units = mg ÷ 0.2).
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard / Gradual Approach (3 mL = 20 mg/mL)

Phase / Week(s)	Dose & Frequency	Volume (U-100 units / mL)
Week 1	20 mg (100 units), 1× daily	100 units (1.0 mL)
Week 2	24 mg/day, split 60u AM + 60u PM	120 units (1.2 mL)
Week 3	28 mg/day, split 70u AM + 70u PM	140 units (1.4 mL)
Week 4+	32 mg/day, split 80u AM + 80u PM	160 units (1.6 mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 60 mg vial → final concentration 20 mg/mL. (Applies to a research-grade lyophilized powder only.)
Typical daily range: 20 mg/day (Week 1), titrated to 24, 28 then 32 mg/day; from Week 2 onward the daily amount is split into AM and PM injections.
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg on a U-100 syringe, so units = mg ÷ 0.2 (e.g. 20 mg = 100 units, 32 mg = 160 units).
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: Week 1 is a single daily dose; from Week 2 the daily amount is split into a morning and an evening injection as the total rises[3][4]. This subcutaneous, powder-based scheme is an educational reconstruction only and does not reflect how clinical Cerebrolysin is actually given.

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Reality check: real commercial Cerebrolysin is a ready-to-use liquid concentrate (215.2 mg/mL) supplied in glass ampoules and given intramuscularly or intravenously by clinicians — never subcutaneously, with no reconstitution. The lyophilized-powder, subcutaneous protocol described here applies only to a research-grade powder and is educational, not standard medical practice. Avoid freezing the reconstituted solution.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of once-daily injections with gradual titration.

Quantities depend on the daily dose; one 60 mg vial covers roughly 2–3 days at 20–32 mg/day.
8 weeks: ~27 vials
12 weeks: ~42 vials
16 weeks: ~57 vials
Per injection: 1 syringe
8 weeks (AM+PM from Wk 4): ~95 syringes
16 weeks (AM+PM from Wk 4): ~200 syringes
Use ~3.0 mL per 60 mg vial for reconstitution.
8 weeks (8 vials): ~24 mL → 3 bottles
16 weeks (16 vials): ~48 mL → 5 bottles
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
8 weeks (once daily): ~112 swabs → 1–2 boxes

Protocol Overview

A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.

▪Goal: Cerebrolysin is hypothesized to provide neurotrophic support relevant to stroke, dementia and TBI — effects largely inferred from preclinical work and not proven in humans; a 2022 Cochrane review found insufficient evidence in acute ischemic stroke[5][6].
▪Schedule: Daily subcutaneous injections for 8–12 weeks, optionally extended to ~16 weeks for longer research goals.
▪Dose Range: 20 mg/day in Week 1, titrated to 24, 28 then 32 mg/day, with the daily total split AM/PM from Week 2 onward.
▪Reconstitution: 3.0 mL bacteriostatic water per 60 mg vial gives 20 mg/mL (research-powder scheme only; clinical Cerebrolysin is a ready-to-use liquid).
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A suggested daily titration approach based on common reference doses.

▪Start: Begin at 20 mg once daily (Week 1) to gauge tolerability.
▪Titrate: Increase by about 4 mg each week (24, 28, then 32 mg/day) as tolerated, splitting the dose AM/PM from Week 2.
▪Target: Reach about 32 mg daily by Week 4 and hold there.
▪Cycle Length: Typically 8–12 weeks; some references extend to ~16 weeks.
▪Timing: Inject at a consistent time each day and rotate injection sites systematically.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: Cerebrolysin is not FDA-approved in the US (no NDA), though it is marketed in 50+ countries abroad; it is also a porcine-derived biological product carrying the usual biologic-sourcing considerations[10].

How This Works

Cerebrolysin is a porcine (pig) brain-derived mixture of low-molecular-weight neuropeptides and free amino acids, produced by enzymatic breakdown of pig brain tissue[1][2]. It is not a single defined molecule but a complex biological mixture.

Its proposed mechanism is to mimic endogenous neurotrophic factors such as BDNF, NGF and GDNF, potentially supporting neuronal survival, plasticity and repair[5][6]. This mechanism is largely inferred from preclinical work and has not been proven in humans.
Cerebrolysin is approved and marketed in 50+ countries across Europe, Russia, Asia and Latin America for stroke, dementia and traumatic brain injury[11], but the clinical evidence is mixed and inconclusive — a 2022 Cochrane review found insufficient evidence to support its use in acute ischemic stroke[12].
Important caveat: Cerebrolysin is not FDA-approved in the United States (no NDA on file). Cognitive and neuroprotective benefits should not be overstated — the strongest claims rest on heterogeneous trials and preclinical models, and high-quality evidence remains limited.
Cerebrolysin is not approved in the United States. This page is presented for educational and informational purposes only and is not medical advice.

Lifestyle Factors

Habits that may support recovery alongside the protocol.

▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs.
▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase.
▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
▪Stress: Manage stress with evidence-based practices, since it influences overall healing.

Potential Benefits & Side Effects

What the international clinical and preclinical literature describes; the human evidence base is mixed and inconclusive, and individual results vary.

▪Neurotrophic support (preclinical): Cerebrolysin is hypothesized to mimic BDNF/NGF/GDNF activity and has shown neuroprotective signals in animal models[5][6].
▪Approved use abroad: Used clinically in 50+ countries for stroke, dementia and TBI, though trial results are heterogeneous[11].
▪Tolerability: Generally reported as well tolerated in clinical use abroad, with mostly mild adverse effects.
▪Evidence caveat: Benefits are not firmly established — a 2022 Cochrane review found insufficient evidence in acute ischemic stroke, and it is not FDA-approved in the US[13].
▪Common effects: Dizziness, headache, sweating, mild agitation or injection-site reactions have been reported.
▪US status: Not FDA-approved in the US, so it is not subject to US manufacturing oversight; sourcing and quality vary.
▪Porcine source: It is a pig-brain-derived biological mixture, which carries the usual biologic-sourcing and allergy considerations.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[14][15].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

Cerebrolysin is a porcine-derived biological mixture and is generally not sold as a research peptide. For high-purity research peptides and supplies more broadly, we point researchers to Prime Lab Peptides.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for Cerebrolysin 60mg.

Cerebrolysin (60mg Vial) Dosage Protocol Open source
1 Journal of Neural Transmission Composition and neurotrophic hypothesis of Cerebrolysin: a porcine-brain-derived mixture of neuropeptides and amino acids. View Source ↗ Open source
2 CNS & Neurological Disorders (PubMed) Pharmacological characterization of Cerebrolysin and its proposed BDNF/NGF/GDNF-like neurotrophic actions. View Source ↗ Open source
3 U.S. FDA — Drug Approvals Regulatory status overview: Cerebrolysin is not FDA-approved in the United States (no NDA on file). View Source ↗ Open source
4 EVER Neuro Pharma (Manufacturer) International approvals: Cerebrolysin is marketed in 50+ countries for stroke, dementia and TBI. View Source ↗ Open source
5 Stroke (AHA Journal, PubMed) Preclinical evidence for neuroprotective and neurotrophic effects of Cerebrolysin in animal models. View Source ↗ Open source
6 Frontiers in Neuroscience (PubMed) Cerebrolysin neurotrophic activity: experimental support for neuronal survival and plasticity. View Source ↗ Open source
7 Peptide Storage Guide Best practices for storing lyophilized peptides (temperature, humidity and light protection). View Source ↗ Open source
8 Bacteriostatic Water Guidance Bacteriostatic water for injection: multi-dose vial stability and handling. View Source ↗ Open source
9 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and site rotation. View Source ↗ Open source
10 Neuropsychiatric Disease & Treatment (PubMed) Cerebrolysin clinical use in traumatic brain injury and dementia: summary of indications abroad. View Source ↗ Open source
11 Journal of Alzheimer’s Disease Cerebrolysin in vascular and Alzheimer-type dementia: clinical trial findings (heterogeneous results). View Source ↗ Open source
12 Cochrane Database of Systematic Reviews Cochrane review (2022): insufficient evidence for Cerebrolysin in acute ischemic stroke. View Source ↗ Open source
13 ClinicalTrials.gov ClinicalTrials.gov registry of Cerebrolysin studies across stroke, TBI and dementia indications. View Source ↗ Open source
14 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
15 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
16 Cerebrolysin Prescribing Information Cerebrolysin product information — ampoule liquid concentrate (215.2 mg/mL) for IM/IV use abroad. View Source ↗ Open source

Contents